highly significantp < 0.001
7.1%, p = 0.40), with a highly significant decrease in bleeding (2.4 vs. 4.1%, p < 0.001; Lincoff et al., 2003 ).
7.1%, p = 0.40), with a highly significant decrease in bleeding (2.4 vs. 4.1%, p < 0.001; Lincoff et al., 2003 ).
The net clinical benefit endpoint (death, MI, or major bleeding), approached significance at 30 days (HR 0.90, CI 0.76–1.00, p = 0.051; Murphy et al., 2007 ).